Topical Delgocitinib for Capecitabine-Induced Hand–Foot Syndrome: A Therapeutic Option?
- 1Dermatology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy
- 2Department of Medical and Surgical Sciences, Alma Mater Studiorum, University of Bologna, Via Giuseppe Massarenti 5, 40138 Bologna, Italy
Abstract
Introduction: Hand–foot syndrome (HFS) is a frequent and potentially dose-limiting adverse event of capecitabine. Current therapeutic strategies are not always effective. Since inflammatory pathways, including JAK-STAT3 signaling, may contribute to capecitabine-induced HFS, topical JAK inhibition could represent a potential therapeutic approach.
Methods: We report two women with metastatic breast cancer receiving capecitabine monotherapy who developed Common Terminology Criteria for Adverse Events (CTCAE) grade 3 HFS involving both palms and soles. Both patients had previously received clobetasol propionate 0.05% combined with urea 30%, with only transient benefit. Delgocitinib 20 mg/g cream was subsequently applied twice daily to palms and soles for 6 weeks. Treatment response was assessed clinically and using the HFS-14 quality-of-life scale.
Results: Capecitabine dose and schedule remained unchanged in both patients throughout the 6-week delgocitinib treatment period. In patient 1, HFS improved from CTCAE grade 3 to grade 1, with marked symptomatic improvement and a decrease in HFS-14 score from 73.5 to 17.6. Capecitabine was continued unchanged, and the clinical improvement remained stable during an additional 3 months of follow-up. In patient 2, erythema decreased, but desquamation and burning persisted; HFS remained CTCAE grade 3 and the HFS-14 score decreased from 76.5 to 67.6. Capecitabine was therefore interrupted after the week 6 assessment. No local or systemic adverse events related to delgocitinib were observed.
Conclusion: Topical delgocitinib may represent a potential therapeutic strategy for capecitabine-induced HFS, particularly in patients who do not adequately respond to topical corticosteroid therapy. However, the discordant responses observed in these two cases highlight that its therapeutic role remains uncertain and requires further prospective investigation.
Related
- Iatrogenic Cushing Syndrome With Glucocorticoid-Induced Adrenal Insufficiency Following Prolonged Topical Clobetasol Use in an Adolescent
- Topical Glyceryl Trinitrate for Levator Ani Syndrome: Promising Findings Requiring Prospective Confirmation
- Therapeutic Potential of Bone Marrow-Derived Mesenchymal Stem Cells in A Letrozole-Induced Rat Model of Polycystic Ovary Syndrome
- Tripelennamine 1% topical cream versus diphenhydramine 1% topical cream for the relief of histamine-induced itching: A proof-of-concept study in healthy adults.
- Lyell's syndrome associated with the use of topical agents: case report
BibTeX
@article{rapparini2026topical,
title = {{Topical Delgocitinib for Capecitabine-Induced Hand–Foot Syndrome: A Therapeutic Option?}},
author = {Luca Rapparini and Ginevra Martelli and Stephano Cedirian and Francesca Pampaloni and Francesca Bruni and Michela Starace},
journal = {Dermatology and Therapy},
year = {2026},
month = oct,
doi = {10.1007/s13555-026-01947-z},
url = {https://doi.org/10.1007/s13555-026-01947-z},
note = {CC BY-NC 4.0},
}
RIS
TY - JOUR
TI - Topical Delgocitinib for Capecitabine-Induced Hand–Foot Syndrome: A Therapeutic Option?
AU - Luca Rapparini
AU - Ginevra Martelli
AU - Stephano Cedirian
AU - Francesca Pampaloni
AU - Francesca Bruni
AU - Michela Starace
PY - 2026
DA - 2026/10/07
JO - Dermatology and Therapy
DO - 10.1007/s13555-026-01947-z
UR - https://doi.org/10.1007/s13555-026-01947-z
AB - Introduction: Hand–foot syndrome (HFS) is a frequent and potentially dose-limiting adverse event of capecitabine. Current therapeutic strategies are not always effective. Since inflammatory pathways, including JAK-STAT3 signaling, may contribute to capecitabine-induced HFS, topical JAK inhibition could represent a potential therapeutic approach. Methods: We report two women with metastatic breast cancer receiving capecitabine monotherapy who developed Common Terminology Criteria for Adverse Events (CTCAE) grade 3 HFS involving both palms and soles. Both patients had previously received clobetasol propionate 0.05% combined with urea 30%, with only transient benefit. Delgocitinib 20 mg/g cream was subsequently applied twice daily to palms and soles for 6 weeks. Treatment response was assessed clinically and using the HFS-14 quality-of-life scale. Results: Capecitabine dose and schedule remained unchanged in both patients throughout the 6-week delgocitinib treatment period. In patient 1, HFS improved from CTCAE grade 3 to grade 1, with marked symptomatic improvement and a decrease in HFS-14 score from 73.5 to 17.6. Capecitabine was continued unchanged, and the clinical improvement remained stable during an additional 3 months of follow-up. In patient 2, erythema decreased, but desquamation and burning persisted; HFS remained CTCAE grade 3 and the HFS-14 score decreased from 76.5 to 67.6. Capecitabine was therefore interrupted after the week 6 assessment. No local or systemic adverse events related to delgocitinib were observed. Conclusion: Topical delgocitinib may represent a potential therapeutic strategy for capecitabine-induced HFS, particularly in patients who do not adequately respond to topical corticosteroid therapy. However, the discordant responses observed in these two cases highlight that its therapeutic role remains uncertain and requires further prospective investigation.
SN - 2193-8210
SN - 2190-9172
SN - 1476-5829
ER -